keyword
MENU ▼
Read by QxMD icon Read
search

Lurasidone

keyword
https://www.readbyqxmd.com/read/29788232/chronic-stress-exposure-reduces-parvalbumin-expression-in-the-rat-hippocampus-through-an-imbalance-of-redox-mechanisms-restorative-effect-of-the-antipsychotic-lurasidone
#1
Andrea C Rossetti, Maria Serena Paladini, Martina Colombo, Piotr Gruca, Magdalena Lason-Tyburkiewicz, Katarzyna Tota-Glowczyk, Mariusz Papp, Marco A Riva, Raffaella Molteni
Background: Psychiatric disorders are associated with altered function of inhibitory neurotransmission within the limbic system, which may be due to the vulnerability of selective neuronal subtypes to challenging environmental conditions, such as stress. In this context, parvalbumin (PVB) positive GABAergic interneurons, which are critically involved in processing complex cognitive tasks, are particularly vulnerable to stress exposure, an effect that may be the consequence of dysregulated redox mechanisms...
May 18, 2018: International Journal of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29763637/neurosteroid-pregnenolone-sulfate-alone-and-as-augmentation-of-lurasidone-or-tandospirone-rescues-phencyclidine-induced-deficits-in-cognitive-function-and-social-interaction
#2
L Rajagopal, D Soni, H Y Meltzer
BACKGROUND: Pregnenolone sulfate (PregS), an endogenous neurosteroid, which negatively and positively modulates gamma amino butyric acid subunit A (GABAA ) and N-methyl D-aspartate (NMDA) receptors (R) respectively, among other potential neuroplastic changes on synaptic processes, has shown some beneficial effects on treating cognitive impairment associated with schizophrenia (CIAS) and negative symptoms. Lurasidone (Lur), an atypical antipsychotic drug (AAPD), and tandospirone (Tan), a 5-HT1A  R partial agonist, have also been reported to improve cognitive or negative symptoms, or both, in some schizophrenia patients...
May 12, 2018: Behavioural Brain Research
https://www.readbyqxmd.com/read/29756288/mixed-states-in-bipolar-and-major-depressive-disorders-systematic-review-and-quality-appraisal-of-guidelines
#3
REVIEW
N Verdolini, D Hidalgo-Mazzei, A Murru, I Pacchiarotti, L Samalin, A H Young, E Vieta, A F Carvalho
OBJECTIVE: This systematic review provided a critical synthesis and a comprehensive overview of guidelines on the treatment of mixed states. METHOD: The MEDLINE/PubMed and EMBASE databases were systematically searched from inception to March 21st, 2018. International guidelines covering the treatment of mixed episodes, manic/hypomanic, or depressive episodes with mixed features were considered for inclusion. A methodological quality assessment was conducted with the Appraisal of Guidelines for Research and Evaluation-AGREE II...
May 13, 2018: Acta Psychiatrica Scandinavica
https://www.readbyqxmd.com/read/29732910/lurasidone-adjunctive-with-antidepressants-in-an-elderly-patient-with-severe-illness-anxiety-disorder
#4
Pei-Yin Pan, Chin-Bin Yeh
No abstract text is available yet for this article.
May 1, 2018: Australian and New Zealand Journal of Psychiatry
https://www.readbyqxmd.com/read/29730043/identifying-the-genetic-risk-factors-for-treatment-response-to-lurasidone-by-genome-wide-association-study-a-meta-analysis-of-samples-from-three-independent-clinical-trials
#5
Jiang Li, Antony Loebel, Herbert Y Meltzer
A genome-wide association study (GWAS) of response of schizophrenia patients to the atypical antipsychotic drug, lurasidone, based on two double-blind registration trials, identified SNPs from four classes of genes as predictors of efficacy, but none were genome wide significant (GWS). After inclusion of data from a third lurasidone trial, meta-analysis identified a GWS marker and other findings consistent with our first study. The primary end-point was change in Total Positive and Negative Syndrome Scale (PANSS) between baseline and last observation carried forward...
May 2, 2018: Schizophrenia Research
https://www.readbyqxmd.com/read/29697278/efficacy-and-metabolic-effects-of-lurasidone-versus-brexpiprazole-in-schizophrenia-a-network-meta-analysis
#6
Daisy Ng-Mak, Vanita Tongbram, Kerigo Ndirangu, Krithika Rajagopalan, Antony Loebel
AIM: To assess the relative efficacy and metabolic effects of lurasidone and brexpiprazole in the acute treatment of schizophrenia. METHODS: Five lurasidone and three brexpiprazole trials were identified. In the absence of head-to-head trials, a Bayesian network meta-analysis comparing lurasidone and brexpiprazole was performed. RESULTS: Nonstatistically significant differences in efficacy measures were observed between lurasidone and brexpiprazole...
April 26, 2018: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/29679069/pharmacological-treatment-of-adult-bipolar-disorder
#7
REVIEW
Ross J Baldessarini, Leonardo Tondo, Gustavo H Vázquez
We summarize evidence supporting contemporary pharmacological treatment of phases of BD, including: mania, depression, and long-term recurrences, emphasizing findings from randomized, controlled trials (RCTs). Effective treatment of acute or dysphoric mania is provided by modern antipsychotics, some anticonvulsants (divalproex and carbamazepine), and lithium salts. Treatment of BD-depression remains unsatisfactory but includes some modern antipsychotics (particularly lurasidone, olanzapine + fluoxetine, and quetiapine) and the anticonvulsant lamotrigine; value and safety of antidepressants remain controversial...
April 20, 2018: Molecular Psychiatry
https://www.readbyqxmd.com/read/29670547/medications-used-for-cognitive-enhancement-in-patients-with-schizophrenia-bipolar-disorder-alzheimer-s-disease-and-parkinson-s-disease
#8
REVIEW
Wen-Yu Hsu, Hsien-Yuan Lane, Chieh-Hsin Lin
Background/aims: Cognitive impairment, which frequently occurs in patients with schizophrenia, bipolar disorder, Alzheimer's disease, and Parkinson's disease, has a significant impact on the daily lives of both patients and their family. Furthermore, since the medications used for cognitive enhancement have limited efficacy, the issue of cognitive enhancement still remains a clinically unsolved challenge. Sampling and methods: We reviewed the clinical studies (published between 2007 and 2017) that focused on the efficacy of medications used for enhancing cognition in patients with schizophrenia, bipolar disorder, Alzheimer's disease, and Parkinson's disease...
2018: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/29666740/treatment-of-acute-psychosis-with-second-generation-antipsychotics-in-a-patient-with-left-temporal-lobe-lesion
#9
Richard Shehane, Steve Miller, Luke Suber, Miranda Chakos
We present a case of rapid onset severe psychosis followed by suicide attempt in a United States Navy sailor. Investigation revealed a left temporal lobe brain mass suspicious for low-grade glioma. After hospitalization and medical management with olanzapine and lurasidone the patient's psychosis improved. The purpose of this paper is to add to the existing case reports that suggest a relationship between temporal lobe lesions and psychiatric illness, specifically psychosis. In addition, this case adds insight into the effectiveness of medical therapy for brain tumor patients that are not immediate candidates for neurosurgical intervention...
2018: Case Reports in Psychiatry
https://www.readbyqxmd.com/read/29625538/hospitalization-risk-in-bipolar-disorder-patients-treated-with-lurasidone-versus-other-atypical-antipsychotics
#10
Daisy Ng-Mak, Rachel Halpern, Krithika Rajagopalan, Antony Loebel
OBJECTIVE: This observational study compared the risk of hospitalization for patients with bipolar disorder when treated with lurasidone versus other oral atypical antipsychotics. METHODS: This U.S. commercial claims analysis (April 4, 2010 through September 24, 2014) used the Optum Research Database to identify adult patients with bipolar disorder treated with oral atypical antipsychotics (N = 11,132). The first claim for an atypical antipsychotic defined the index date, with pre-index and post-index periods of 180 and 360 days, respectively...
April 6, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29620693/longer-term-effectiveness-and-tolerability-of-adjunctive-open-lurasidone-in-patients-with-bipolar-disorder
#11
Shefali Miller, Dennis Do, Anda Gershon, Po W Wang, Farnaz Hooshmand, Lauren S Chang, Terence A Ketter
PURPOSE: To retrospectively assess lurasidone effectiveness/efficacy/tolerability in bipolar disorder (BD) patients. METHODS: Outpatients assessed with Systematic Treatment Enhancement Program for BD Affective Disorders Evaluation received naturalistically administered (primarily adjunctive) open lurasidone while monitored at visits with the Systematic Treatment Enhancement Program for BD Clinical Monitoring Form. RESULTS: Sixty-one patients (32 type I, 26 type II, 3 type not otherwise specified; mean ± SD age, 45...
June 2018: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29618351/hospitalization-outcomes-in-patients-with-schizophrenia-after-switching-to-lurasidone-or-quetiapine-a-us-claims-database-analysis
#12
John W Newcomer, Daisy Ng-Mak, Krithika Rajagopalan, Antony Loebel
BACKGROUND: This study compared hospital admission rates among adult patients with schizophrenia who switched to antipsychotic monotherapy with lurasidone or quetiapine. METHODS: This retrospective cohort study used U.S.-based Truven Health MarketScan® Medicaid Multi-State Database (April 2010 through December 2012) and MarketScan® Commercial Claims and Encounters Database (April 2010 through October 2013). Continuous enrollment for 6-months before and after medication initiation was required...
April 4, 2018: BMC Health Services Research
https://www.readbyqxmd.com/read/29607004/a-prospective-year-long-follow-up-of-lurasidone-use-in-clinical-practice-factors-predicting-treatment-persistence
#13
Ian J Osborne, Shubhra Mace, David Taylor
Background: Our aim was to follow up patients prescribed lurasidone over 1 year to determine factors predicting treatment persistence. Methods: We used noninterventional, observational, prospective follow up of patients consecutively prescribed lurasidone in a large inner-city NHS mental health trust. We also performed retrospective analysis of outcomes from patient case notes. Results: Data were available for 69 patients consecutively prescribed lurasidone, of whom three (4%) were lost to follow up...
April 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29536616/canadian-network-for-mood-and-anxiety-treatments-canmat-and-international-society-for-bipolar-disorders-isbd-2018-guidelines-for-the-management-of-patients-with-bipolar-disorder
#14
Lakshmi N Yatham, Sidney H Kennedy, Sagar V Parikh, Ayal Schaffer, David J Bond, Benicio N Frey, Verinder Sharma, Benjamin I Goldstein, Soham Rej, Serge Beaulieu, Martin Alda, Glenda MacQueen, Roumen V Milev, Arun Ravindran, Claire O'Donovan, Diane McIntosh, Raymond W Lam, Gustavo Vazquez, Flavio Kapczinski, Roger S McIntyre, Jan Kozicky, Shigenobu Kanba, Beny Lafer, Trisha Suppes, Joseph R Calabrese, Eduard Vieta, Gin Malhi, Robert M Post, Michael Berk
The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published treatment guidelines for bipolar disorder in 2005, along with international commentaries and subsequent updates in 2007, 2009, and 2013. The last two updates were published in collaboration with the International Society for Bipolar Disorders (ISBD). These 2018 CANMAT and ISBD Bipolar Treatment Guidelines represent the significant advances in the field since the last full edition was published in 2005, including updates to diagnosis and management as well as new research into pharmacological and psychological treatments...
March 2018: Bipolar Disorders
https://www.readbyqxmd.com/read/29497196/oculogyric-crisis-with-atypical-antipsychotics-a-case-series
#15
Naresh Nebhinani, Navratan Suthar
Oculogyric crisis (OGC) is an acute dystonic reaction, commonly seen with the administration of typical antipsychotics, and rarely reported with atypical antipsychotics. Here, we report five cases of oculogyric crisis, developed after administration of atypical antipsychotics. The first case developed OGC on quetiapine 800 mg/day and the second case on olanzapine 20 mg/day. Both the patients did not improve on adding anticholinergic agents and finally stabilized by switching to clozapine. The third case developed OGC on amisulpride 400 mg and lurasidone 40 mg/day and improved by reducing amisulpride dose to 200 mg and stopping lurasidone...
October 2017: Indian Journal of Psychiatry
https://www.readbyqxmd.com/read/29436643/neuroprotective-effect-of-lurasidone-via-antagonist-activities-on-histamine-in-a-rat-model-of-cranial-nerve-involvement
#16
Baoming He, Liang Yu, Suping Li, Fei Xu, Lili Yang, Shuai Ma, Yi Guo
Cranial nerve involvement frequently involves neuron damage and often leads to psychiatric disorder caused by multiple inducements. Lurasidone is a novel antipsychotic agent approved for the treatment of cranial nerve involvement and a number of mental health conditions in several countries. In the present study, the neuroprotective effect of lurasidone by antagonist activities on histamine was investigated in a rat model of cranial nerve involvement. The antagonist activities of lurasidone on serotonin 5‑HT7, serotonin 5‑HT2A, serotonin 5‑HT1A and serotonin 5‑HT6 were analyzed, and the preclinical therapeutic effects of lurasidone were examined in a rat model of cranial nerve involvement...
April 2018: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29410937/understanding-antipsychotic-drug-treatment-effects-a-novel-method-to-reduce-pseudospecificity-of-the-positive-and-negative-syndrome-scale-panss-factors
#17
REVIEW
Seth C Hopkins, Ajay Ogirala, Antony Loebel, Kenneth S Koblan
The Positive and Negative Syndrome Scale (PANSS) is the most widely used efficacy measure in acute treatment studies of schizophrenia. However, interpretation of the efficacy of antipsychotics in improving specific symptom domains is confounded by moderate-to-high correlations among standard (Marder) PANSS factors. The authors review the results of an uncorrelated PANSS score matrix (UPSM) transform designed to reduce pseudospecificity in assessment of symptom change in patients with schizophrenia. Based on a factor analysis of five pooled, placebo-controlled lurasidone clinical trials (N=1,710 patients), a UPSM transform was identified that generated PANSS factors with high face validity (good correlation with standard Marder PANSS factors), and high specificity/orthogonality (low levels of between-factor correlation measuring change during treatment)...
December 1, 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29410934/insight-and-treatment-outcomes-in-schizophrenia-post-hoc-analysis-of-a-long-term-double-blind-study-comparing-lurasidone-and-quetiapine-xr
#18
Philip D Harvey, Cynthia O Siu, Antony D Loebel
Objective: The objective of this post-hoc analysis was to evaluate the effect of lurasidone and quetiapine extended-release (XR) on insight and judgment and assess the longitudinal relationships between improvement in insight and cognitive performance, functional capacity, quality of well-being, and depressive symptoms in patients with schizophrenia. Design: Clinically unstable patients with schizophrenia (N=488) were randomized to once-daily, fixed-dose treatment with lurasidone 80mg, lurasidone 160mg, quetiapine XR 600mg, or placebo, followed by a long-term, double-blind, flexible-dose continuation study involving these agents...
December 1, 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29357776/comparison-of-lurasidone-versus-quetiapine-for-the-treatment-of-delirium-in-critically-ill-patients
#19
Marlena A Fox, Jessica L Elefritz, Brandon M Huang, Charles Hunley
OBJECTIVE: To evaluate the efficacy and safety of lurasidone compared with quetiapine for treatment of delirium in critically ill patients. DESIGN: Prospective, observational cohort study. SETTING: Single-center community teaching hospital. PATIENTS: Forty adult intensive care unit (ICU) patients with delirium (Confusion Assessment Method in the ICU positive), tolerating enteral nutrition, and without active alcohol withdrawal or prior use of atypical antipsychotics...
January 1, 2018: Journal of Intensive Care Medicine
https://www.readbyqxmd.com/read/29246268/sleep-related-orgasms-in-a-57-year-old-woman-a-case-report
#20
Muna Irfan, Carlos H Schenck
We report a case of problematic spontaneous orgasms during sleep in a 57-year-old woman who also complained of hypnic jerks and symptoms of exploding head syndrome. To our knowledge, this is the first case report in the English language literature of problematic spontaneous orgasms during sleep. She had a complex medical and psychiatric history, and was taking oxycontin, venlafaxine, amitriptyline, and lurasidone. Prolonged video electroencephalogram monitoring did not record any ictal or interictal electroencephalogram discharges, and nocturnal video polysomnography monitoring did not record any behavioral or orgasmic event...
January 15, 2018: Journal of Clinical Sleep Medicine: JCSM: Official Publication of the American Academy of Sleep Medicine
keyword
keyword
27111
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"